| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 1.22 | -0.04 (-3.17%) | 1.01 - 2.94 | 98.2 thousand (Below Avg) |
Market data as of 3:59PM 06/19/13. Quotes are delayed by at least 15 min.
| Open | 1.26 |
|---|---|
| Previous Close | 1.26 |
| Day's Range | 1.22 - 1.28 |
| Market Cap | 29.8M |
| Avg Volume (10 Day) | 240.0K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.85 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Pass |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Leading Independent Proxy Advisory Firms ISS and Glass, Lewis & Co., LLC Recommend Vote “FOR” BioSante/ANI Merger
Business Wire - Monday 06/10/2013 9:00 AM ET
| BPAX | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 373.78% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.31 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | -- | |
| Price/Sales | 13.23 |
| Company | Last | Change |
|---|---|---|
| Verenium Corp | 2.30 | +0.44% |
| Idera Pharmaceuticals Inc | 0.68 | -8.11% |
| Cardiome Pharma Corp | 2.02 | -1.94% |
| Merus Labs International Inc | 0.83 | +3.30% |
| Ibio Inc | 0.45 | +6.93% |
Data is delayed by at least 15 min.